Expert Rev of Obstet Gynecol. 2010;5(6):673-686. Each year worldwide, over 380,000 women die from pregnancy and pregnancy-related causes. If contraception were made available to unprotected women, ...

Use of depot medroxyprogesterone acetate (DMPA) weakens both innate and adaptive immune responses to HIV type 1 (HIV-1) and, therefore, reduces host resistance to the infection, new data suggest. DMPA ...

Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV ...

A National Dissemination Event of Key Findings on “A National Policy Landscape Analysis on DMPA SC as Self-Injection in Pakistan” took place on July 27, 2023, organized by RIZ Consulting and Jhpiego.

Use of DMPA associated with HIV risk Recent data suggest that use of depot medroxyprogesterone acetate may increase women's HIV acquisition risk. Evidence observed in an updated systematic review ...

A new review of research suggests that women using the injectable contraceptive depot-medroxyprogesterone acetate or DMPA might be at higher risk of HIV infection by as much at 40%. Medical ...

Several studies have linked depot medroxyprogesterone acetate (DMPA) use with reduced BMD. Walsh and colleagues' case–control study assessed whether this BMD deficit is age-specific and/or ...

SEATTLE – April 4, 2012 – The first large-scale U.S.-based study to evaluate the link between an injectable form of progestin-only birth control and breast cancer risk in young women has found that ...